Compare BILL & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BILL | ATAI |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2019 | 2025 |
| Metric | BILL | ATAI |
|---|---|---|
| Price | $47.44 | $7.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 8 |
| Target Price | ★ $57.90 | $15.88 |
| AVG Volume (30 Days) | 2.6M | ★ 8.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,160,000.00 | $4,089,000.00 |
| Revenue This Year | $14.18 | N/A |
| Revenue Next Year | $13.83 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.03 | ★ 1227.60 |
| 52 Week Low | $31.41 | $3.27 |
| 52 Week High | $57.21 | $7.45 |
| Indicator | BILL | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.40 | 72.67 |
| Support Level | $46.72 | $3.89 |
| Resistance Level | $49.60 | N/A |
| Average True Range (ATR) | 1.97 | 0.05 |
| MACD | -0.44 | -0.07 |
| Stochastic Oscillator | 29.69 | 68.52 |
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.